Fibroids - Is There an Alternative to Surgical Therapy?

Fibroids, or uterine fibroids, are benign tumors that form in the uterus and are common in women of childbearing age. They can cause various symptoms, including heavy and prolonged menstrual periods, abdominal pain, a sensation of pressure in the pelvis, as well as urinary or sexual problems.

Traditional Treatment

Traditionally, fibroids were often surgically removed, but this method carries potential risks and complications. An alternative therapeutic option was Esmya, a medication developed to treat fibroids. Esmya was found to be effective in reducing the size of fibroids and relieving symptoms. However, the medication had to be withdrawn from the market after reports of serious liver problems in some patients were reported, despite its effectiveness.

Alternative Therapeutic Options

Antihormone therapies have also been used to slow or stop the growth of fibroids. However, these treatments can have serious side effects and are therefore rarely used or only for short periods.

In some situations, fibroids can also be treated with other methods, such as Sonata treatment or embolization, which involve blocking the blood supply to the fibroids, thereby reducing their size and relieving symptoms.

Ryeqo® - A Promising New Option

A promising new option is Ryeqo®, a medication approved in Europe for the long-term treatment of fibroids. Ryeqo® contains a combination of active ingredients, including relugolix, which reduces the production of estrogen and progesterone, thereby alleviating symptoms associated with fibroids. Unlike other treatments, Ryeqo® offers the possibility of long-term continuous treatment without the need for invasive surgical intervention.

Warnings and Precautions

In some patients, the use of Ryeqo® may not be appropriate. Specifically, women at high risk of osteoporotic fractures or thromboembolic events should be carefully monitored before starting treatment. A thorough medical history is necessary to assess individual risk. In case of signs of thromboembolic events or liver diseases, the use of Ryeqo® should be immediately discontinued.

It is important for patients to be informed about potential symptoms and warning signs indicating serious side effects. This includes signs of heart attack, stroke, deep vein thrombosis, or pulmonary embolism. In case of such symptoms, immediate medical assistance is necessary.

Conclusion

For women suffering from fibroids, Ryeqo® represents an effective and well-tolerated alternative that can improve their quality of life, offering a glimmer of hope for a non-invasive and long-lasting therapy.

Best regards,

Dr. Sandra Yene Amougui